GUSELKUMAB, AN ANTI-INTERLEUKIN-23P19-SUBUNIT MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO WERE BIOLOGIC-NAIVE OR PRIOR TNFα INHIBITOR-TREATED: WEEK 24 RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

被引：0
|
作者：
Deodhar, Atul [1 ]
Helliwell, Philip [2 ]
Boencke, Wolf-Henning [3 ]
Hsia, Elizabeth C. [4 ,5 ,6 ]
Kollmeier, Alexa P. [4 ,5 ]
Subramanian, Ramanand A. [4 ,5 ]
Xu, Xie L. [4 ,5 ]
Sheng, Shihong [4 ,5 ]
Zhou, Bei [4 ,5 ]
Zazzetti, Federico [7 ]
Ritchlin, Christopher [8 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Univ Leeds, Leeds, W Yorkshire, England
[3] Geneva Univ Hosp, Geneva, Switzerland
[4] Janssen Res & Dev LLC, Spring House, PA USA
[5] Janssen Res & Dev LLC, San Diego, CA USA
[6] Univ Penn, Med Ctr, Philadelphia, PA 19104 USA
[7] Janssen LATAM Med Affairs, Buenos Aires, DF, Argentina
[8] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
来源：
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2020年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
298
引用
收藏
页码：24 / 24
页数：1
相关论文
共 50 条
  • [21] Efficacy and Safety Results of Guselkumab, an Anti-IL23 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis over 24 Weeks: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study
    Deodhar, Atul A.
    Gottlieb, Alice B.
    Boehncke, Wolf-Henning
    Dong, Bin
    Wang, Yuhua
    Barchuk, William
    Xu, Xie
    Hsia, Elizabeth C.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [22] Efficacy and safety of guselkumab, an anti-IL23 Monoclonal antibody, in patients with active psoriatic arthritis: A phase 2a, randomized, double-blind, placebo-controlled study
    Gottlieb, Alice
    Deodhar, Atul
    Boehncke, Wolf-Henning
    Dong, Bin
    Wang, Yuhua
    Barchuk, William
    Hsia, Elizabeth
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB111 - AB111
  • [23] Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
    Mease, Philip J.
    van der Heijde, Desiree
    Ritchlin, Christopher T.
    Okada, Masato
    Cuchacovich, Raquel S.
    Shuler, Catherine L.
    Lin, Chen-Yen
    Braun, Daniel K.
    Lee, Chin H.
    Gladman, Dafna D.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (01) : 79 - 87
  • [24] Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naive or TNFα inhibitor-experienced
    Ritchlin, Christopher T.
    Helliwell, Philip S.
    Boehncke, Wolf-Henning
    Soriano, Enrique R.
    Hsia, Elizabeth C.
    Kollmeier, Alexa P.
    Chakravarty, Soumya D.
    Zazzetti, Federico
    Subramanian, Ramanand A.
    Xu, Xie L.
    Zuraw, Qing C.
    Sheng, Shihong
    Jiang, Yusang
    Agarwal, Prasheen
    Zhou, Bei
    Zhuang, Yanli
    Shawi, May
    Karyekar, Chetan S.
    Deodhar, Atul
    RMD OPEN, 2021, 7 (01):
  • [25] Effect of Certolizumab Pegol On Signs and Symptoms in Patients with Psoriatic Arthritis with and without Prior Anti-TNF Exposure: 24 Week Results of a Phase 3 Double-Blind Randomized Placebo-Controlled Study
    Mease, Philip
    Fleischmann, Roy M.
    Wollenhaupt, Juergen
    Deodhar, Atul A.
    Kielar, Danuta
    Woltering, Franz
    Stach, Christian
    Hoepken, Bengt
    Arledge, Terri
    van der Heijde, Desiree
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S1107 - S1107
  • [26] Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial (vol 395, pg 1126, 2020)
    Mease, P. J.
    Rahman, P.
    Gottlieb, A. B.
    LANCET, 2020, 395 (10230): : 1114 - 1114
  • [27] Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFa inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial (vol 395, pg 1115, 2020)
    Deodhar, A.
    Helliwell, P. S.
    Boehncke, W-H
    LANCET, 2020, 395 (10230): : 1114 - 1114
  • [28] The Effect of Guselkumab on Work Productivity in Biologic-Naive Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial
    Curtis, Jeffrey R.
    McInnes, Iain B.
    Rahman, Proton
    Gladman, Dafna D.
    Peterson, Steven
    Agarwal, Prasheen
    Yang, Feifei
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Shiff, Natalie J.
    Zhou, Bei
    Han, Chenglong
    Shawi, May
    Tillett, William
    Mease, Philip J.
    ADVANCES IN THERAPY, 2022, 39 (10) : 4613 - 4631
  • [29] Efficacy and safety of guselkumab in biologic-naive patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
    Gladman, Dafna D.
    Mease, Philip J.
    Bird, Paul
    Soriano, Enrique R.
    Chakravarty, Soumya D.
    Shawi, May
    Xu, Stephen
    Quinn, Sean T.
    Gong, Cinty
    Leibowitz, Evan
    Poddubnyy, Denis
    Tam, Lai-Shan
    Helliwell, Philip S.
    Kavanaugh, Arthur
    Deodhar, Atul
    Ostergaard, Mikkel
    Baraliakos, Xenofon
    TRIALS, 2022, 23 (01)
  • [30] The Effect of Guselkumab on General Health State in Biologic-Naive Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial
    Curtis, Jeffrey R.
    McInnes, Iain B.
    Rahman, Proton
    Gladman, Dafna D.
    Yang, Feifei
    Peterson, Steven
    Agarwal, Prasheen
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Han, Chenglong
    Shiff, Natalie J.
    Shawi, May
    Tillett, William
    Mease, Philip J.
    ADVANCES IN THERAPY, 2022, 39 (10) : 4632 - 4644
12345